Abstract 739P
Background
The DESTINY-PanTumor02 trial demonstrated efficacy of HER2-directed antibody drug conjugates (ADCs) in the treatment of gynecologic malignancies, including EEA. Trial eligibility was determined utilizing HER2 IHC gastric criteria, but many institutions historically use breast criteria for IHC interpretations. As neither scoring system has been validated in gynecologic neoplasms, our study seeks to compare them in EEA.
Methods
Blinded pathology review of HER2 IHC (4B5) from 263 randomly selected EEAs was performed by two board-certified pathologists utilizing gastric and breast criteria. Results of the two scoring systems were compared (Positive [P]: intensity 3+, >10% [breast] or ≥10% [gastric] tumor cell staining, Equivocal [E]: 2+, >10% [breast] or ≥10% [gastric], Low/Negative [N]: >1+, ≤10% [breast] or <10% [gastric], or any percentage of 1+). Tumors were analyzed for ERBB2 copy number amplification by DNA (592-gene or whole exome) sequencing and statistical significance determined using unpaired T-test.
Results
Of HER2 P cases, 96% (49/51) were concordant between breast/gastric criteria, median of 13.0 copies of ERBB2. HER2 E tumors showed a lower rate of concordance with 51% (30/59) concordant cases, median of 2.5 copies of ERBB2. Of discordant HER2 E tumors, 44% (26/59) of E cases were N by breast/E by gastric (1.8 median copies, p < 0.02 vs concordant cases). HER2 N cases were 86% (155/182) concordant (1.9 median copies, p = 0.96 vs N by breast/E by gastric cases).
Conclusions
While gastric and breast criteria demonstrated 96% concordance in identifying EEAs positive for HER2 overexpression, equivocal staining was more often documented with gastric scoring. This greater frequency of equivocal results may suggest a preference for gastric criteria in the assessment of EEA, matching trial inclusion criteria where clinical benefit of HER2 ADCs has been established in patients with HER2 equivocal tumors. Table: 739P
Concordance and discordance of HER2 IHC calls by gastric and breast criteria
IHC Call | Gastric | |||
P | E | N | ||
Breast | P | 49 | 1 | 0 |
E | 1 | 30 | 1 | |
N | 0 | 26 | 155 |
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
M.G. Evans: Financial Interests, Personal, Invited Speaker: Caris Life Sciences; Financial Interests, Personal, Full or part-time Employment: Caris Life Sciences; Financial Interests, Personal, Stocks/Shares: Caris Life Sciences. H. Krause: Financial Interests, Institutional, Full or part-time Employment, I am a full time employee at Caris Life Sciences: Caris Life Sciences. A. Elliott: Financial Interests, Personal, Full or part-time Employment: Caris Life Sciences. C. Mathews: Financial Interests, Institutional, Research Funding: AstraZeneca, Tesaro/GSK, Astellas Pharma, Seattle Genetics, Deciphera, Moderna, Regeneron, Roche/Genentech, Pfizer, Laekna Therapeutics, EMD Serono, Merck, Genmab, Avenge Bio, Zentalis, ImmunoGen, Elucida Oncology, Artios, Volastra Therapeutics, AADI, Repare Therapeutics. S. Wei: Financial Interests, Personal, Other, board member of molecular tumor board of Caris Life Sciences: Caris Life Sciences. J. Hechtman: Financial Interests, Personal, Full or part-time Employment: Caris Life Sciences; Financial Interests, Personal, Speaker, Consultant, Advisor: Pfizer. D. Bryant: Financial Interests, Institutional, Full or part-time Employment, Senior Medical Director of Pathology: Caris Life Sciences; Financial Interests, Personal, Stocks/Shares, Own stock and have stock options: Caris Life Sciences. M. Oberley: Financial Interests, Personal, Full or part-time Employment: Caris Life Sciences; Financial Interests, Personal, Stocks/Shares: Caris Life Sciences. M.A. Powell: Financial Interests, Personal, Speaker, Consultant, Advisor: GSK, Merck, Eisai, AstraZeneca, Seagen, Immunogenicity. P.H. Thaker: Financial Interests, Personal, Advisory Board: Merck, GSK, Seagen, Immunon, ImmunoGen, Novocure, Zentalis; Financial Interests, Personal, Other, consulting: Caris, Verastem; Financial Interests, Personal, Other, DSMB committee: Iovance; Financial Interests, Institutional, Research Grant: Merck, GSK; Financial Interests, Institutional, Coordinating PI: Zentalis, Seagen, ImmunoGen; Financial Interests, Institutional, Local PI: Verastem, Genelux. All other authors have declared no conflicts of interest.
Resources from the same session
621P - Phase II trial of encorafenib and binimetinib (E+B) in patients (pts) with BRAF-altered advanced solid tumors: Results of E+B cohort in the BELIEVE trial (NCCH1901)
Presenter: Yoshitaka Honma
Session: Poster session 01
622P - Safety and efficacy of ifebemtinib (IN10018) combined with D-1553 in solid tumors with KRAS G12C mutation: Results from a phase Ib/II study
Presenter: Zhengbo Song
Session: Poster session 01
624P - Belvarafenib in patients (pts) with BRAF class II or III alteration-positive tumours: TAPISTRY study
Presenter: Rafal Dziadziuszko
Session: Poster session 01
625P - Initial results from the phase I, first-in-human study of the covalent, PI3Kα inhibitor TOS-358 in patients with solid tumors, expressing PI3Kα mutations or amplifications
Presenter: Marwan Fakih
Session: Poster session 01
626P - Roginolisib (IOA-244), a first oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kδ) in patients with metastatic uveal melanoma
Presenter: Anna Di Giacomo
Session: Poster session 01
627P - Long-term efficacy and safety of larotrectinib in non-primary central nervous system (CNS) TRK fusion cancer
Presenter: Alexander Drilon
Session: Poster session 01
628P - Efficacy and safety of larotrectinib as first-line treatment for patients (pts) with TRK fusion cancer: An updated analysis
Presenter: David Hong
Session: Poster session 01
629P - Phase I study of pamiparib and cabozantinib in patients with metastatic solid tumors harboring homologous recombination deficiency (HRD)
Presenter: Siqing Fu
Session: Poster session 01